Method of promoting wound healing

1. A pharmaceutical composition comprising

a) a miR-198 inhibitor and TGF-β1; or

b) a miR-198 inhibitor and a follistatin-like-1 polypeptide; or

c) a follistatin-like-1 (FSTL) polypeptide and TGF-Pβ1; or

d) a miR-198 inhibitor and TGF-β1 and a follistatin-like-1 (FSTL) polypeptide.

2. The pharmaceutical composition of claim 1 , wherein, if present, TGF-β1 is to be present in an amount of between about 10 μg to 300 mg/kg body weight.

3. The pharmaceutical composition of claim 1 , prepared for topical or systemic administration.

4. The pharmaceutical composition of claim 1 , wherein, if present, the miR-198 inhibitor and a follistatin-like-1 (FSTL) polypeptide are to be independently present in an amount of between about 10 μg to 300 mg/kg body weight.

5. The pharmaceutical composition of claim 1 , wherein the miR-198 inhibitor is selected from the group of an anti-miR-198, peptide nucleic acid (PNA) derivatives of miR-198 inhibitor sequence and Tiny locked nucleic acid (LNA) anti-miRs for seed-sequence of the inhibitor.

6. The pharmaceutical composition of claim 1 , wherein the miR-198 inhibitor has the sequence: 5′-GAACCUAUCUCCCCUCUGGACC-3′ (SEQ ID NO: 1).

7. The pharmaceutical composition of claim 6 , wherein the inhibitor is unmodified.

8. The pharmaceutical composition of claim 6 , wherein the inhibitor is with at least one modification selected from the group consisting of 1) full or partial 2′-O-methoxy ethyl modification, 2) full or partial phosphorothioate modification, 3) cholesterol modification of 3′ end of the miR-198 inhibitor and 4) full or partial locked nucleic acid modification (LNA) of nucleotides.